James L. Gulley, MD, PhD

James L. Gulley, MD, PhD, chief of the Genitourinary Malignancies Branch, director of Medical Oncology Service, National Cancer Institute, discusses treatment beyond the second line in bladder cancer. Gulley says there is no standard procedure for the third line setting in bladder cancer, and that most oncologists would either turn to single-agent chemotherapy or to clinical trials.

Videos

Gulley says there is no standard procedure for the third line setting in bladder cancer, and that most oncologists would either turn to single-agent chemotherapy or to clinical trials.

Dr. James L. Gulley on Treatment Beyond the Second Line in Bladder Cancer

James L. Gulley, MD, PhD, chief of the Genitouriniy Malignancies Branch, director of Medical Oncology Service, National Cancer Institute, discusses the potential shift of the treatment paradigm in bladder cancer. Gulley says there are currently a variety of phase III studies looking at new treatments for use in bladder cancer.

Gulley says there are currently a variety of phase III studies looking at new treatments for use in bladder cancer, despite some widely-used agents, such as nivolumab and pembrolizumab, already being approved for other cancer types like melanoma and lung cancer, though not bladder cancer.

Dr. James L. Gulley on Atezolizumab, Pembrolizumab, and Avelumab's Potential Uses in Bladder Cancer

James L. Gulley, MD, PhD, Head, Clinical Trials Group,Deputy Laboratory Chief, National Cancer Institute (NCI), discusses how PROSTVAC works in patients with castration-resistant prostate cancer.

Gulley says the PROSTVAC vaccine was designed to generate an immune response directed against cells that produce prostate-specific antigens (PSA) in patients with prostate cancer. PROSTVAC is given to patients via a subcutaneous injection in the thigh or arm, Gulley says. This is different than an oncolytic virus, which is delivered to the patient via IV.

Once the vaccine is injected, Gulley says, the virus can infect multiple cells, including antigen-presenting cells and dendritic cells. After this, the vaccine then trains the T cells to recognize and attack any cells making PSA, creating a robust immune response, Gulley says. As the T cells learn how to kill the tumor; there can be an expansion of an immune response to kill other targets within the prostate cancer.

PROSTVAC was designed to generate an immune response against PSA in patients with prostate cancer

PROSTVAC is given to patients via a subcutaneous injection in the thigh or arm

Once PROSTVAC is injected, the virus trains the T cells to recognize and attack cells that make PSA

Once the T cells learn how to kill the tumor, there can be an expansion of an immune response to kill other targets within the prostate cancer

James L. Gulley, MD, PhD, discusses how PROSTVAC works in patients with castration-resistant prostate cancer.

James L. Gulley, MD, PhD | Authors

Articles

Dr. James L. Gulley on Treatment Beyond the Second Line in Bladder Cancer

Dr. James L. Gulley on Atezolizumab, Pembrolizumab, and Avelumab's Potential Uses in Bladder Cancer

PROSTVAC in Castration-Resistant Prostate Cancer